作者: Amish C. Shah , Jane E. Minturn , Yimei Li , Jean B. Belasco , Peter C. Phillips
DOI: 10.1002/PBC.25697
关键词:
摘要: Background The high prevalence of carboplatin hypersensitivity reactions (HSR) significantly affects the treatment pediatric patients with low-grade glioma (LGG). Rechallenging is an option that must balance risks repeat allergic reaction to benefits retaining effective anti-tumor regimen. Procedure We performed a retrospective review children LGG treated and vincristine between October 2000 April 2013, who had documented HSR carboplatin. Patients were re-exposed using either precautionary measures (prolonged infusion time premedication H1 antagonists, H2 corticosteroids), desensitization protocol, or both. Results We report results our institutional experience re-exposure both prolonged protocol. Overall, 40 55 (73%) successfully rechallenged carboplatin, including 19 25 (76%) underwent desensitization. Conclusion Our demonstrate be safe alternative abandoning for reaction. We propose clinical algorithm treatment. Pediatr Blood Cancer 2015; 9999:1–6 © 2015 Wiley Periodicals, Inc.